Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
November 07, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO In our previous quarterly report we were able to announce that the first patient had been recruited in our clinical phase III-study. This study is operationally the most...
Lilian Wikström Ph.D. har begärt eget utträde från styrelsen i Infant Bacterial Therapeutics AB
November 05, 2019 11:00 ET
|
Infant Bacterial Therapeutics AB
Lilian Wikström Ph.D. har begärt sitt utträde ur styrelsen i IBT med omedelbar verkan på grund av risk för jäv som har uppstått i hennes roll som VD för KI Innovations AB. Styrelseordförande...
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of Infant Bacterial Therapeutics AB
November 05, 2019 11:00 ET
|
Infant Bacterial Therapeutics AB
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of IBT with immediate effect due to the risk of conflict of interest that has arisen in her role as CEO of KI Innovations AB. ...
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
September 09, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2019
August 21, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2019 VD kommenterar Den 4 juli 2019 kunde vi meddela att den första patienten i IBTs kliniska fas III-studie hade...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019
August 21, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019 Message from the CEO On July 4 we were able to announce that the first patient had been recruited...
Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotala kliniska Fas III-studie
July 04, 2019 08:15 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotala kliniska Fas III-studie, The Connection Study. Utvecklingsprogrammet för IBP-9414, i vilken The Connection Study är den...
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
July 04, 2019 08:15 ET
|
Infant Bacterial Therapeutics AB
IBT has recruited the first patient in the Phase III pivotal clinical study, The Connection Study. The development program for IBP-9414, of which The Connection Study is the final planned clinical...
FDA och Infant Bacterial Therapeutics överens rörande Fas III studiens utformning
May 19, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
IBT har under en längre tid rådgjort med den amerikanska läkemedelsmyndigheten FDA (US Food and Drug Administration) angående hur företagets planerade fas III studie skall utformas. FDA har nu i...
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
May 19, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on how the company's planned Phase III study should be designed. The FDA has now informed IBT in writing that IBT...